Proteomics International Laboratories Ltd (ASX: PIQ) - Share Price
- Current share price for PIQ : $0.115
Proteomics International Laboratories Ltd (PIQ) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a WOS and trading name of PILL, a medical technology company that operates in the fields of precision diagnostics and bio analytical services. The company specialises in proteomics, which involves the study of the structure and function of proteins on an industrial scale. The company's mission is to improve health outcomes through the development and application of tools that support the treatment of disease.
PIQ General Information +
| ASX Code | PIQ |
| Website | http://www.proteomicsinternational.com |
| Industry/Sector | Life Sciences Tools & Services |
| Market Cap ($M) | 19 |
| PIQ Share Price | $0.115 |
| Day High | $0.120 |
| Day Low | $0.115 |
| Last Close | $0.115 |
| PIQ Share Price Movement | - ( No change ) |
Prices as at 16:40, 21 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Proteomics International Laboratories Ltd (PIQ) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Proteomics International Laboratories Ltd (PIQ) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Proteomics International Laboratories Ltd (PIQ) price-sensitive announcements
PIQ - Proteomics International receives $2.0m in R&D tax incentive
Proteomics International Laboratories Ltd announced that it has received a $2.0 million Fe
Proteomics International Laboratories Ltd (PIQ)
21 Oct 2026 | 9:50 AM
21 Oct 2026 | 9:50 AM
PIQ - PromarkerEndo Validation and Refinement Complete
Proteomics International announced it has completed refinement and independent validation
Proteomics International Laboratories Ltd (PIQ)
13 Oct 2026 | 8:43 AM
13 Oct 2026 | 8:43 AM
PIQ - PromarkerD and PromarkerEso Commercial Rollout Update
Proteomics International announced that, under its exclusive Australian pathology distribu
Proteomics International Laboratories Ltd (PIQ)
14 Sep 2026 | 9:47 AM
14 Sep 2026 | 9:47 AM
PIQ - Appendix 4E and Annual Report
Proteomics International Laboratories Ltd’s Appendix 4E and FY2026 Annual Report for the y
Proteomics International Laboratories Ltd (PIQ)
31 Aug 2026 | 4:35 PM
31 Aug 2026 | 4:35 PM
Proteomics International Laboratories Ltd (PIQ) Recent ASX Announcements
PIQ Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$8.61 | -$5.20 | -13.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$8.15 | -$6.00 | 20.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$6.48 | -$5.00 | -5.30% | 0.00 | 0.00 | 0.00% | 0.0% |
PIQ Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Proteomics International Laboratories Ltd (PIQ) | $19M | -0.1374 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
PIQ Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 3.28 | 0.00 |
| Market | 0.30 | 13.50 | 1.04 | 0.71 |
| Sector | 0.78 | 42.90 | 2.55 | 2.04 |
PIQ Directors
| Name | Position | Start Date |
|---|---|---|
| Mr David Morris | Chief Executive Officer, Managing Director | 19 Jan 2026 |
| Mr Paul Edward House | Non-Executive Director | 22 Nov 2017 |
| Ms Vicki Robinson | Non-Executive Director | 14 Oct 2025 |
| Mr Aaron Brinkworth | Non-Executive Director | 8 Nov 2024 |
| Dr James Howard Williams | Non-Executive Director, Non-Executive Chairman | 16 Sep 2024 |
Proteomics International Laboratories Ltd (PIQ) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 21 Nov 2024 | WILLIAMS, James | Issued | Options | 250,000 | $0.185 | $46,267.000 |
| 21 Nov 2024 | LIPSCOMBE, Richard | Issued | Options | 2,600,000 | $0.169 | $439,552.000 |
| 23 Jan 2024 | LIPSCOMBE, Richard | Sell | Direct Shares | 2,631,579 | $0.760 | $2,000,000.000 |
See all changes in directors' interest & trades for Proteomics International Laboratories Ltd (PIQ) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
PIQ Management
| Name | Position |
|---|---|
| Tim Luscombe | Company Secretary,Chief Financial Officer |
PIQ Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Proteomics International Laboratories Ltd (PIQ). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 16,627,902 (10.07%) | Richard John Lipscombe |
PIQ Calendar of Events
| Date | Event |
|---|---|
| 30 August 2027 | Report (Annual) |
| 30 August 2027 | Report (Prelim) |
| 24 February 2027 | Report (Interim) |
| 20 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
